Lcb 2853 | CAS#141335-11-7 | thromboxane A2 receptor antagonist

MedKoo Cat#: 559030 | Name: Lcb 2853

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lcb 2853 is a thromboxane A2 receptor antagonist.

Chemical Structure

Lcb 2853

CAS#141335-11-7

Theoretical Analysis

MedKoo Cat#: 559030

Name: Lcb 2853

CAS#: 141335-11-7

Chemical Formula: C21H23ClNNaO4S

Exact Mass:

Molecular Weight: 443.91

Elemental Analysis: Chemical Formula: Exact Mass: Molecular Weight: Elemental Analysis: C, 56.82; H, 5.22; Cl, 7.99; N, 3.16; Na, 5.18; O, 14.42; S, 7.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lcb 2853; Lcb-2853; Lcb2853;

IUPAC/Chemical Name

sodium 2-(4-((1-(((4-chlorophenyl)sulfonamido)methyl)cyclopentyl)methyl)phenyl)acetate

InChi Key

WVVUYAHTYLRPEB-UHFFFAOYSA-M

InChi Code

InChI=1S/C21H24ClNO4S.Na/c22-18-7-9-19(10-8-18)28(26,27)23-15-21(11-1-2-12-21)14-17-5-3-16(4-6-17)13-20(24)25;/h3-10,23H,1-2,11-15H2,(H,24,25);/q;+1/p-1

SMILES Code

O=C([O-])CC1=CC=C(CC2(CNS(=O)(C3=CC=C(Cl)C=C3)=O)CCCC2)C=C1.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 443.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Depin JC, Vigié A, Chavernac G, Rousselot C, Lardy C, Guerrier D. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Arzneimittelforschung. 1994 Nov;44(11):1203-7. PubMed PMID: 7848332. 2: Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Arzneimittelforschung. 1994 Nov;44(11):1196-202. PubMed PMID: 7848331. 3: Michoud E, Lecomte M, Lagarde M, Wiernsperger N. In vivo effect of 8-epi-PGF2alpha on retinal circulation in diabetic and non-diabetic rats. Prostaglandins Leukot Essent Fatty Acids. 1998 Dec;59(6):349-55. PubMed PMID: 10102379.